임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 18-05-28 14:46
논문번호 204
논문제목(영문) Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial.
국내외구분 국내 SCI여부 KCI
연구책임자역할 교신저자
주저자명 Sim DS
교신저자명 Jeong MH
공동저자명 Sim DS, Jeong MH, Hong YJ, Kim JH, Ahn Y, Park KH, Hwang SH, Kang DG, Lee SU, Kim JW, Park JP, Rhew JY, Lee SR, Chae JK, Yun KH, Oh SK, Kang WY, Kim SH, Cho JH
게제년월일 2018-01-25
ISSN 2233-7385
Impact Factor 0
학술지명 Chonnam medical journal
서지사항 0집 / 54권 / 1호,   페이지(55 - 62)
요약초록문
(Abstract) 입력		 The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease. A total of 488 patients who underwent multivessel percutaneous coronary intervention (PCI) were divided into 2 groups the ER group (n=288) and the ES group (n=200). The primary endpoint was a composite of major adverse cardiac events (MACE) consisting of death, myocardial infarction, and target vessel revascularization after 12 months. In all patients, the prevalence of diabetes was higher in the ER group (42.7% vs. 31.0%, p=0.009). The rate of post-PCI Thrombolysis in Myocardial Infarction flow grade 3 was higher in the ER group (100.0% vs. 98.0%, p=0.028). There were no between-group differences in the in-hospital, 1-month and 12-month clinical outcomes. In the propensity score matched cohort (n=200 in each group), no differences were observed in the baseline and procedural characteristics. There were no statistical differences in the rates of in-hospital, 1-month and 12-month events (12-month MACE in the ER and ES groups: 6.0% vs. 3.5%, p=0.240, respectively). The safety and efficacy of both versions of ZES were comparable in patients with multivessel disease during a 12-month clinical follow-up.
파일  C-204 Safety and Efficacy of the Endeavor Resolute Stent in Patients with Multivessel Disease The HEART Honam EndeAvor ResoluTe Prospective, Multicenter Trial..pdf (476.5K) DATE : 2018-05-28 14:46:37